Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis/Experiment 1
Curated date: 2022/10/09
Curator: Mary Bearkland
Revision editor(s): Mary Bearkland, Davvve, LGeistlinger, Peace Sandy
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Non-responders (Progressive Disease)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Responders (Partial Response or Stable Disease)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with histologically confirmed metastatic or unresectable MSS/MSI-L/pMMR colorectal cancer treated with 80 mg, or 120 mg regorafenib, plus toripalimab resulting in stable disease or partial response.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 21
- Group 1 sample size Number of subjects in the case (exposed) group
- 11
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Any condition requiring ongoing systemic antibiotic therapy
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 3
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
Signature 1
Curated date: 2022/10/09
Curator: Mary Bearkland
Revision editor(s): Mary Bearkland, Aiyshaaaa, Peace Sandy
Source: Supp table S3
Description: Linear discriminant analysis effect size (LDA) from phylum to species level shows differentially enriched taxa in NR and R groups. Related to Figure 4. R, response; NR, non-response.
Abundance in Group 1: increased abundance in Responders (Partial Response or Stable Disease)
| NCBI | Quality Control | Links |
|---|---|---|
| Dialister massiliensis | ||
| Selenomonadales | ||
| Veillonellales | ||
| Paraprevotella |
Revision editor(s): Mary Bearkland, Aiyshaaaa, Peace Sandy
Signature 2
Curated date: 2022/10/09
Curator: Mary Bearkland
Revision editor(s): Mary Bearkland, Aiyshaaaa, Peace Sandy
Source: Supp table S3
Description: Linear discriminant analysis effect size (LDA) from phylum to species level shows differentially enriched taxa in NR and R groups. Related to Figure 4. R, response; NR, non-response.
Abundance in Group 1: decreased abundance in Responders (Partial Response or Stable Disease)
Revision editor(s): Mary Bearkland, Aiyshaaaa, Peace Sandy
